Skip to content

Establishment and Application of an Endoscopic Ultrasonography-Based Evaluation System for Ulcerative Colitis

Establishment and Application of an Endoscopic Ultrasonography-Based Evaluation System for Ulcerative Colitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116497
Enrollment
Unknown
Registered
2026-01-12
Start date
2026-01-12
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lcerative colitis

Interventions

Sponsors

The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age: Age >=18 years old, <=80 years old. (2) Diagnosis: Individuals with clinically active UC manifestations and those previously diagnosed with UC who are currently in remission. (3) Complete baseline clinical data: Laboratory tests such as CRP, erythrocyte sedimentation rate, and calprotectin are available; Be able to describe in detail the disease process, medication history, complications (such as intestinal obstruction, fistula), etc. (4) Pathological evidence: Those who can be examined in conjunction with colonoscopy and ultrasound colonoscopy and undergo tissue sample testing. (5) Informed consent: Willing to sign the informed consent form and recognize the purpose and process of participating in this study.

Exclusion criteria

Exclusion criteria: (1) Complicated with severe diseases: There are serious cardiovascular diseases, liver diseases, kidney diseases and other comorbidities that affect the study. (2) Recent surgery: Patients who have undergone other major surgeries in the recent period (<=6 months). (3) And other intestinal diseases: such as intestinal tumors, polyps, and diverticulitis other than colon cancer. (4) Mental illness: Patients with a severe history of mental illness or cognitive impairment that affects their understanding and participation in the research. (5) Pregnant or lactating women: Women who are pregnant or lactating during the study period.

Design outcomes

Secondary

MeasureTime frame
Clinical remission rate;Biochemical remission rate;Surgery rate;All-cause mortality;EUS-related adverse event rate;

Primary

MeasureTime frame
Transmural healing rate;Histologic healing rate;Mucosal healing rate;

Countries

China

Contacts

Public ContactQu Bo

The Second Affiliated Hospital of Harbin Medical University

qubo_1970@hotmail.com+86 451 8660 5404

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026